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accounting	 for	 6%	 of	 total	 births	worldwide	 (1-4).	 Of	 these	 congenital	 disorders,	
there	are	over	6,000	known	monogenic	diseases	caused	by	a	single-gene	mutation,	
occurring	 with	 a	 frequency	 of	 1-2	 in	 every	 100	 births	 (5,	 6).	 Some	 of	 the	 most	
common	genetic	pediatric	disorders,	such	as	cystic	 fibrosis,	sickle	cell	anemia,	and	
β-	thalassemia,	are	caused	by	single	mutations	and	these	diseases	carry	significant	
lifelong	 morbidity	 and	 mortality	 for	 afflicted	 patients	 (6).	 	 Cystic	 fibrosis	 (CF)	
exemplifies	the	unmet	burden	of	congenital	disorders	 in	that	 it	 is	 the	second	most	
common	lethal	inherited	disorder	of	childhood,	is	rigorously	characterized,	and	yet	
no	 cure	 has	 been	 discovered	 for	 the	 most	 common	 variant,	 a	 three	 base-pair	




As	 treatment	 modalities	 for	 congenital	 disorders	 have	 advanced,	 so	 has	 the	
detection	 of	 these	 diseases.	 Fetal	 diagnoses	 of	 genetic	 disorders	 can	 be	made	 by	
well-established	 methods	 of	 amniocentesis,	 chorionic	 villous	 sampling,	 or	
preimplantation	 genetic	 diagnosis	 (9-11).	 More	 recently,	 non-invasive	 testing	 of	
maternal	blood	for	fragments	of	fetal	DNA	has	been	validated.	This	method	provides	




The	 possibility	 of	 earlier	 fetal	 diagnosis	 opens	 the	 door	 for	 earlier	 intervention.	
Since	 the	 1980’s,	 the	 umbilical	 vessels	 of	 the	 fetus	 have	 been	 safely	 cannulated	
under	ultrasound	guidance	as	 early	 as	12	weeks	gestation	 for	procedures	 such	as	
blood	transfusions	and	drug	delivery.	 In	trained	hands,	 the	risk	of	 fetal	 loss	 is	 less	
than	 1%	 in	 these	 procedures	 (14).	 Similarly,	 amniocentesis	 has	 been	 a	 safe	 and	
approved	procedure	since	the	1970’s	with	an	equally	low	risk	of	fetal	mortality	(11).	




approach	 to	 cure	 genetic	 diseases	 (15),	 there	 exist	 several	 barriers	 to	 successful	
execution	of		curative	correction	strategies	such	as	gene	editing.	One	such	obstacle	
is	cell	targeting.	Ex	vivo	methods	of	gene	editing	to	access	desired	hematopoietic	cell	
types	 have	 shown	 partial	 success;	 however,	 these	 methods	 are	 cumbersome	 and	
limited	to	hematologic	diseases	(16).	In	vivo	methods	have	been	attempted	in	which	
naked	DNA	of	the	correct	genotype	is	injected	into	the	patient’s	blood	stream	in	the	
hope	 that	 the	 correct	 cells	 or	 tissues	 are	 targeted.	 Unsurprisingly,	 this	 practice	
proved	to	be	neither	practical	nor	efficient	(17).	In	order	to	successfully	deliver	any	




To	address	 this	obstacle,	 there	has	been	a	 rapid	growth	of	 research	 in	 the	area	of	
nanoscience	 for	 medical	 applications,	 including	 the	 delivery	 of	 drugs	 and	 other	
therapeutic	 agents	 via	 nanoparticles	 (18-22).	 Nanoparticles	 have	 been	 used	 as	
stable	and	modifiable	vessels	 to	 safely	deliver	drugs	and	small	molecules,	 thereby	
increasing	the	circulation	time	and	decreasing	the	overall	dosage	required	(18,	20).	
Several	 polymers	 have	 been	 approved	 by	 the	 FDA	 for	 use	 in	medical	 devices	 and	
drug	 delivery	 systems,	 such	 as	 poly(lactic	 acid)	 (PLA)	 and	 poly(lactic-co-glycolic	
acid)	 (PLGA).	 The	 advantages	 of	 these	 polymers	 include	 their	 biocompatibility,	





drugs	 (26,	 27),	 water-soluble	 drugs	 (28),	 various	 nucleic	 acids	 (28-32),	 siRNA	
molecules	(28,	29,	31,	32),	proteins	(26),	and	plasmid	DNA	(33).	Additionally,	gene	
editing	via	nanoparticles	has	been	successfully	demonstrated.	In	published	work	by	
our	 colleagues,	 PLGA	 nanoparticles	 loaded	 with	 a	 non-nuclease	 based	 editing	
construct	 have	 been	 shown	 to	 efficiently	 and	 safely	 mediate	 gene	 correction	 in	
human	cells	in	vitro,	cells	treated	ex	vivo,	and	in	animal	models	in	vivo	(34-38).	Gene	
editing	 carries	 advantages	 over	 gene	 replacement	 therapies,	 which	 are	 typically	
delivered	 by	 viral	 vectors.	 Gene	 editing	 leaves	 gene	 products	 under	 native	
regulation,	is	not	limited	to	the	cassette	size	of	viral	vectors,	and	does	not	carry	the	
risk	 of	 tumor	 formation	 from	 non-specific	 insertion	 of	 gene	 products	 (17,	 39).	
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Because	the	editing	construct	repairs	the	mutation	in	situ,	the	correction	is	passed	
down	 to	 all	 progeny	 of	 the	 corrected	 cell	 (35,	 36).	 This	 permanent,	 and	 indeed	
exponential,	effect	is	especially	appealing	in	context	of	fetal	gene	editing	where	stem	
cells	that	create	and	maintain	developing	tissues	can	be	accessed.	When	faced	with	
the	 wide	 range	 and	 scope	 of	 congenital	 disorders,	 nanoparticles	 offer	 endless	
flexibility	as	a	vessel	to	deliver	a	diverse	range	of	therapeutic	interventions.	
	
There	 are	 several	 elements	 to	 successful	 nanoparticle	 targeting	 that	 must	 be	
considered,	 though	 are	 often	 not	 simultaneously	 addressed	 (40).	 These	 variables	
include	 both	 the	 route	 and	 timing	 of	 nanoparticle	 administration,	 as	 well	 as	 the	
molecular	 characteristics	 of	 the	 nanoparticles	 (41,	 42).	 In	 our	 fetal	 model,	 two	
routes	 of	 administration	 exist:	 intravenously	 through	 the	 intravitelline	 vein	 and	
intra-amniotically.	 The	 biodistribution	 of	 nanoparticles	 is	 likely	 dependent	 on	 the	
route	of	injection.	Therefore,	knowing	in	which	organs	the	particles	accumulate	can	
optimize	 efficacy	 of	 therapy.	 For	 example,	 as	 the	 liver	 participates	 in	 first-pass	
filtration	of	the	blood	returning	to	the	fetus	through	the	vitelline	vein,	it	is	likely	that	
intravenous	injections	will	result	in	a	greater	accumulation	of	nanoparticles	in	this	
organ	 and	 hepatic	 or	 hematopoietic	 disorders	 could	 be	 more	 easily	 targeted.	
Furthermore,	knowledge	of	 the	developmental	stage	of	 the	 fetus	can	be	harnessed	
to	optimize	the	temporal	targeting	of	nanoparticles.	It	is	known	that	fetuses	begin	to	
breathe	 and	 swallow	amniotic	 fluid	during	 gestation	 to	 aid	 in	development	of	 the	
pulmonary	 and	 gastrointestinal	 systems	 (43,	 44).	 If	 intra-amniotic	 injections	 are	
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have	been	used	by	our	group	are	known	 to	be	 internalized	by	many	different	 cell	
types.	 The	 uptake	 of	 nanoparticles	 into	 cells	 is	 predominantly	 mediated	 by	
endocytic	mechanisms,	with	 subsequent	 escape	 of	 the	 internalized	 particles	 from	
the	 endosomes	 (24,	 45).	 The	 kinetics	 of	 nanoparticle	 uptake	 are	 dependent	 on	
multiple	 different	 characteristics	 of	 the	 particles	 that	 can	 be	 altered,	 such	 as	 size,	
shape,	and	surface	properties	(24,	46,	47).	Surface	properties	of	nanoparticles	have	
been	modified	with	 the	 addition	of	proteins	 (33,	48-50),	 cell-penetrating	peptides	
(23,	29,	51),	receptor	ligands	(31),	and	cell-specific	antibodies	(52,	53).	Considering	
that	 particle	 uptake	 is	 mediated	 by	 endocytosis,	 which	 requires	 contact	 of	 the	




Conjugation	 of	 specific	 antibodies	 to	 nanoparticles	 increases	 particle	 functionality	
by	 prolonging	 cell	 surface	 binding,	 as	well	 as	 actively	 targeting	 specific	 cell	 types	
(53-55).	 Currently,	 a	 large	 focus	of	 targeted	nanoparticles	has	been	 in	 the	 field	of	
cancer	 therapeutics,	where	much	of	 the	development	 of	 active	 targeting	has	 been	
realized	 (56,	 57).	 Our	 work	 proposes	 an	 alternative	 and	 novel	 use	 for	 targeting	
	 6	
nanoparticles.	 Prior	 studies	 from	 our	 group	 have	 shown	 that	 gene	 editing	
nanoparticles	 delivered	 intranasally	 to	 adult	mice	with	 cystic	 fibrosis	 achieve	 1%	
editing	in	lung	tissue	(58).	While	not	phenotypically	relevant,	these	results	indicate	




groups	 can	be	harnessed	 for	 antibody	 conjugation	by	 carboxyl	 amine	 crosslinking	
(53).	 The	 use	 of	 antibody-conjugated	 nanoparticles	 has	 been	 shown	 to	 improve	
uptake	efficiency	in	cells	and	tissues	(53)	and	this	technology	has	been	approved	for	
use	in	clinical	trials	(59,	60).	Importantly,	the	presence	of	antibody	targeting	ligands	
does	 not	 alter	 the	 biodistribution	 of	 nanoparticles	 in	 vivo	 (41,	 61-64).	 These	
polymer	 nanoparticles,	 therefore,	 present	 a	 safe,	 biocompatible,	 and	 targetable	
method	of	delivering	therapeutics	to	cells	and	tissues.			
	
The	 therapeutic	 potential	 of	 loaded	 nanoparticle	 delivery	 could	 be	 further	
maximized	 by	 treating	 early	 during	 development.	 In	utero	 delivery	 of	 treatments,	
including	gene	editing	 reagents,	 could	mitigate	 the	burden	of	 congenital	disorders	
that	afflict	millions	of	patients	around	the	world.	As	a	clinical	patient,	the	fetus	offers	
several	 potential	 therapeutic	 advantages	 over	 the	 post-natal	 host	 (65).	 The	
developing	 fetus	 is	 composed	 of	 a	 proportionally	 greater	 number	 of	 stem	 and	
progenitor	 cells,	 which	 can	 exponentially	 increase	 the	 potency	 of	 gene	 editing	
strategies.	 Additionally,	 stem	 cells	 of	 the	 brain,	 skin,	 muscle,	 liver,	 and	 blood	 are	
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more	susceptible	to	editing	during	development	due	to	their	massive	proliferation	
and	migration	 (66-70).	 Furthermore,	 in	utero	 intervention	 takes	 advantage	 of	 the	
fetus’	 immature	 (and	 therefore	 immunotolerant)	 immune	 system	 as	 well	 as	 the	
fetus’	 small	 relative	 size.	 To	 give	 the	 same	 dose-per-weight	 of	 nanoparticles	 in	 a	







this	 thesis	 is	 that	 optimization	 of	 nanoparticle	 delivery	 and	 targeting	 by	
considering	 both	 nanoparticle	modification	 and	 the	 route	 of	 administration	
can	 increase	 the	 overall	 uptake	 of	 particles	 in	 specific	 cells	 and	 tissues	 of	
interest.	The	application	of	targeting	nanoparticle	technology	can	improve	upon	the	
current	 therapies	 in	 adult	 tissues,	 while	 implementing	 this	 technology	 in	 a	 novel	









Specific	 Aim	 3:	 To	 determine	 conjugation-dependent	 uptake	 of	 targeting	
nanoparticles.		
This	is	innovative	because	targeting	technology	has	not	been	applied	in	the	scope	of	









Poly(lactic-co-glycolic	 acid)	 (PLGA)	 nanoparticles	 (NPs)	 were	 made	 with	 50:50	
ester-terminated,	 5-10kDa	MW	PLGA	 polymer	 obtained	 from	 LACTEL	 Absorbable	
Polymers.	 Fluorescent	 dyes	 used	were	 Coumarin	 6	 (C6)	 (Ex	 =	 460	nm,	 Em	=	 500	
nm)	 obtained	 from	 Sigma,	 used	 at	 final	 wt	 dye/wt	 polymer	 ratio	 of	 2%,	 or	 3,3′-





Dyes	 were	 dissolved	 in	 dimethyl	 sulfoxide	 (DMSO),	 added	 to	 PLGA	 dissolved	 in	
dichloromethane	(DCM),	and	diluted	to	the	correct	concentration.	The	polymer-dye	
mixture	was	added	dropwise	under	vortex	to	5%	polyvinyl	alcohol	(PVA)	in	water	
and	 sonicated.	 This	 emulsion	 was	 poured	 into	 0.3%	 PVA	 in	 water	 and	 stirred	 at	
room	 temperature	 for	 3	 hours.	 NPs	 were	 collected	 by	 centrifugation	 and	
reuspended	in	water.	One	aliquot	was	removed	for	dynamic	light	scattering	(DLS).	





PLGA	 NPs	 were	 also	 formulated	 using	 the	 NanoAssemblr	 Benchtop	 system	 by	
Precision	Nanosystems.	Dyes	were	dissolved	in	DMSO,	added	to	PLGA	dissolved	in	
10%	DMSO	 in	acetonitrile,	 and	diluted	 to	 the	 correct	 concentration.	The	polymer-
dye	 mixture	 was	 injected	 through	 the	 organic	 inflow	 channel	 of	 the	 microfluidic	
mixer	 and	 a	 2%	 PVA	 in	 water	 solution	 was	 injected	 through	 the	 aqueous	 inflow	
channel	 of	 the	 microfluidic	 mixer.	 The	 NPs	 were	 created	 with	 a	 1:1	 flow	 rate	 of	
aqueous	 to	organic	 solvents,	8	ml/min	 total	 flow	rate,	 and	2	ml	 total	volume.	NPs	
were	collected	in	water.	One	aliquot	was	removed	for	DLS.	Solvent	was	removed	by	
centrifugation	and	washing.	NPs	were	 then	 frozen	at	 -80°C	and	 lyophilized	 for	48	
hours	 in	preweighed	Eppendorf	 tubes.	 Final	weight	 of	 dehydrated	NPs	was	noted	
and	NPs	were	stored	at	-20°C.	
	





Polylactic	 acid	 –	 polyethylene	 glycol	 (PLA-PEG)	 polymer	 was	 16-5	 kDal	 MW	 and	
obtained	 from	PolySciTech.	DiO	 fluorescent	dye	at	0.5%	w/w	was	encapsulated	 in	
the	NPs.	Fluorescent	PLGA	nanoparticles	were	formulated	by	two	methods.	
	




was	 added	 dropwise	 under	 vortex	 to	 deionized	 water.	 NPs	 were	 then	 filtered	
through	 1.2	 μm	 cellulose	 acetate	 membrane	 to	 remove	 free	 dye	 or	 polymer	
aggregates.	 One	 aliquot	was	 removed	 for	DLS.	NPs	were	 left	 stirring	 overnight	 to	




PLA-PEG	NPs	were	 also	 formulated	 using	 the	NanoAssemblr	 Benchtop	 system	 by	
Precision	Nanosystems.	Dyes	were	dissolved	in	DMSO,	added	to	PLGA	dissolved	in	
75%	DMSO	 in	acetonitrile,	 and	diluted	 to	 the	 correct	 concentration.	The	polymer-
dye	 mixture	 was	 injected	 through	 the	 organic	 inflow	 channel	 of	 the	 microfluidic	
mixer	 and	 water	 was	 injected	 through	 the	 aqueous	 inflow	 channel	 of	 the	
microfluidic	mixer.	The	NPs	were	created	with	a	1:1	flow	rate	of	aqueous	to	organic	
solvents,	 2	 ml/min	 total	 flow	 rate,	 and	 2	ml	 total	 volume.	 NPs	 were	 collected	 in	
water.	One	aliquot	was	 removed	 for	DLS.	Solvent	was	 removed	by	 tangential	 flow	
filtration	 using	 the	 KR2i	 TFF	 System	 from	 Spectrum	 Labs.	 NP	 batches	 were	
concentrated	by	a	factor	of	10	to	a	final	volume	of	5ml	and	dialyzed	10	times.	One	
























Appropriate	 targets	 were	 selected	 by	 literature	 review	 and	 with	 aid	 from	 the	
LungGENS	database	(72).	Selection	criteria	required	that	the	targets	be	cell-surface	
markers,	 present	 on	 epithelial	 cells,	 and	 present	 in	 pulmonary	 tissues.	 Targets	
present	 in	 fetal	 lungs	 were	 also	 selected	 for	 use	 in	 the	 in	 utero	 mouse	 model.	
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Accessibility	 of	 the	 antigens	was	 analyzed	 by	 immunofluorescent	 staining	 of	 both	
CFBE	cells	and	sections	of	fetal	and	adult	mouse	lung	to	confirm	surface	expression	
of	 the	 target.	Cells	were	 fixed	with	4%	paraformaldehyde	(PFA)	 for	15	minutes	at	
room	temperature	and	then	washed	with	PBS.	Tissues	were	fixed	with	4%	PFA	prior	
to	 sectioning;	 frozen	 sections	 of	 thickness	 14-16	 μm	 were	 made.	 Samples	 were	
blocked	 with	 FBS	 for	 one	 hour	 at	 room	 temperature	 and	 then	 incubated	 with	
primary	 antibody	 at	 1:100	 overnight	 at	 4°C.	 Sections	 were	 subsequently	 washed	
with	 PBS	 and	 incubated	 with	 the	 appropriate	 species	 of	 secondary	 antibody	
conjugated	to	Alexa	Fluor	488	fluorophore	(Ex	=	490nm,	Em	=	525nm)	for	3	hours	
at	 room	 temperature.	 Sections	 were	 again	 washed	 and	 then	 counterstained	 with	
DAPI	 and	 mounted	 for	 analysis	 by	 confocal	 microscopy.	 Confocal	 imaging	 was	
performed	on	a	Zeiss	Cell	Observer	SD	microscope.		
	
Receptor	 density	 and	 antibody-antigen	 affinity	 were	 determined	 by	 antibody	
titration	curves	(53,	74).	Cells	in	96-well	plates	were	treated	in	triplicate	with	60	μl	
of	media	containing	primary	antibody	in	concentrations	ranging	from	0.1	nM	to	100	
nM.	 The	 corresponding	 isotype	 antibody	was	 used	 as	 a	 control	 for	 each	 antibody	
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species.	 The	 cells	 were	 incubated	 for	 one	 hour	 at	 37°C.	 Cells	 were	 washed	 with	
media,	treated	with	30nM	concentration	of	secondary	antibody	conjugated	to	Alexa	
Fluor	 488	 fluorophore	 in	 cell	 culture	media,	 and	 incubated	 again	 for	 one	 hour	 at	
37°C.	 Cells	 were	 washed	 and	 trypsonized	 with	 0.25%	 trypsin.	 Cold	 fluorescence-
activated	 cell	 sorting	 (FACS)	 buffer	 (2%	 fetal	 bovine	 serum	 in	 sterile	 PBS)	 was	
added	to	each	well	and	cells	were	collected	in	individual	FACS	tubes	and	kept	on	ice	
for	analysis.	FACS	was	performed	on	an	Attune	NxT	Flow	Cytometer	by	Invitrogen.	
Untreated	 cells	 were	 used	 to	 determine	 forward-	 and	 side-scatter	 voltages	 and	
background	 fluorescence	 was	 subtracted	 from	 all	 experimental	 groups.	 FlowJo	
software	was	used	for	FACS	analysis.	Intensity	data	generated	was	used	to	create	a	





Antibody	 conjugation	 to	 PLA-PEG	 NPs	 occurred	 via	 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide	hydrochloride	(EDC)	mediated	carboxyl-amine	
crosslinking.	 Antibodies	 containing	 sodium	 azide	 or	 other	 preservatives	 were	
dialyzed	 overnight	 to	 remove	 any	 molecules	 that	 could	 inhibit	 coupling.	 The	






57	 μl	 of	 100	 mg/ml	 sulfo-(N-hydroxysulfosuccinimide)	 (NHS)	 was	 added	 under	







complete,	 the	 supernatant	 was	 carefully	 aspirated	 and	 the	 activated	 NPs	 were	
resuspended	in	50	μl	of	50	mM	MES	in	PBS.	The	activated	NPs	were	then	added	to	




NP	 solution.	The	NPs	were	 then	micro-centrifuged	 at	 21,500g	 for	10	minutes	 and	
the	supernatant	was	carefully	aspirated.	The	conjugated	NPs	were	resuspended	 in	








Human	 bronchial	 epithelial	 cells	 (16HBE	 O-14))	 and	 cystic	 fibrosis	 bronchial	
epithelial	 cells	 (CFBE41o-)	 (an	 immortalized	 cell	 line	 homozygous	 for	 the	 F508	







well	 plates.	 Confluent	 cells	 in	 flask	 were	 washed	 with	 PBS,	 treated	 with	 TrypLE	







CFBE	 cells	 were	 seeded	 in	 48-well	 plates.	 Each	 batch	 of	 antibody-conjugated	
nanoparticles	 was	 tested	 at	 three	 concentrations:	 25	 μg/ml,	 50	 μg/ml,	 and	 100	
μg/ml,	in	500	μl	total	volume	of	cell	culture	media.	Isotype-conjugated	nanoparticles	
were	 used	 as	 matched	 controls	 for	 each	 experimental	 antibody.	 Cells	 were	
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incubated	with	the	conjugated	NPs	for	2	hours	at	37°C.	The	cells	were	subsequently	
washed	 six	 times	 with	 warm	 FACS	 buffer	 before	 being	 trypsonized	 with	 0.25%	
trypsin.	 Cold	 FACS	 buffer	 was	 added	 to	 each	 well	 and	 cells	 were	 collected	 in	
individual	 FACS	 tubes	 and	 kept	 on	 ice	 for	 analysis.	 Fluorescence-activated	 cell	
sorting	 (FACS)	 was	 performed	 on	 an	 Attune	 NxT	 Flow	 Cytometer	 by	 Invitrogen.	
Untreated	 cells	 were	 used	 to	 determine	 forward-	 and	 side-scatter	 voltages	 and	






All	 animal	 use	was	 in	 accordance	with	 the	 guidelines	 of	 the	Animal	 Care	 and	Use	
Committee	of	Yale	University.	Mice	used	were	C57BL/6	mice	obtained	from	Charles	
River	Laboratories	as	well	as	654-EGFP	mice	that	are	genetically	modified	to	contain	




To	 determine	 the	 gestational	 age	 at	 which	 mouse	 fetuses	 begin	 to	 breathe	 and	





For	 each	 procedure,	 the	 pregnant	 female	 mice	 were	 anesthesized	 with	 inhaled	






final	 concentration	 of	 9	mg/ml.	 The	 NPs	were	 vortexed	 and	 sonicated	 to	 achieve	
complete	 resuspension.	 Intra-vascular	 injections	 were	 performed	 at	 E15.5	 and	





a	 pneumatic	 microinjector.	 Intra-amniotic	 injections	 were	 performed	 at	 E15.5,	
E16.5,	E17.5,	and	E18.5	(FIGURE	1B).	The	injections	were	performed	by	myself	and	
Adele	 Ricciardi	 using	 hand-drawn	 glass	micropipettes.	 A	 volume	 of	 20	 μl	 of	 dye-
loaded	 PLGA	 NPs	was	 drawn	 up	 and	 injected	 directly	 into	 the	 amniotic	 cavity	 of	
each	fetus.		
	
Pregnant	 mice	 were	 sacrificed	 3	 hours	 post	 NP	 injection	 and	 the	 fetuses	 were	
delivered	by	cesarean	section.	Confirmation	of	successful	 injection	was	done	by	ex	
vivo	fetal	fluorescence	stereomicroscope	imaging	on	a	Leica	M80	stereomicroscope	
(FIGURE	 1C).	 Fetuses	 were	 then	 fixed	 en	 bloc	 in	 4%	 PFA	 for	 24	 hours	 and	
subsequently	 dehydrated	 in	 20%	 sucrose.	 Specimens	 were	 then	 embedded	 in	






then	 transferred	 to	 20%	 sucrose	 for	 dehydration.	 The	 fixed	 tissues	 were	 then	
embedded	in	OCT	compound	and	frozen.	Frozen	sections	were	counterstained	with	





at	whole-fetus	 and	organ-specific	 fluorescent	uptake.	 For	 these	 studies,	PLGA	NPs	
were	loaded	with	1,1-dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine	(DiD)	dye	
(Ex	 =	 644	 nm,	 Em	 =	 665	 nm)	 for	 compatibility	 with	 the	 imaging	 system.	




The	 author	 was	 responsible	 for	 execution	 of	 all	 cell	 culture	 experiments,	
nanoparticle	 fabrication	 and	 conjugation,	 intra-amniotic	 nanoparticle	 injections,	
collection	 and	 analysis	 of	 all	 injected	 fetuses	 including	 sectioning,	 staining,	 and	
microscopy.	Intra-venous	injections	were	performed	by	Dr.	David	Stitelman	and	Dr.	
James	 Farrelly.	 Whole	 fetus	 fluorescent	 xray	 imaging	 was	 performed	 by	 Adele	












well	 as	 two	 different	 methods	
of	 synthesis	 for	 each	 polymer	
type.	 Preliminary	 experiments	
were	 performed	 to	 develop	
size	 curves	 to	 ensure	
consistency	 in	 size	 and	
distribution	 of	 NPs,	 regardless	
of	fabrication	method.	The	size	
curve	shown	 in	FIGURE	2	was	
created	 for	 fluorescent	 dye-
encapsulated	 PLA-PEG	 NPs	 synthesized	 using	 the	 NanoAssemblr.	 By	 altering	 the	
starting	 concentration	 of	 the	 polymer,	 the	 diameter	 of	 the	 nanoparticles	 can	 be	
consistently	 altered.	 For	 PLA-PEG	 NPs,	 a	 starting	 concentration	 of	 30	 mg/ml	
resulted	 in	 150nm	 particles.	 	 However,	 for	 PLGA	NPs,	 a	 starting	 concentration	 of	




NPs	 remained	 consistent	 for	 lower	 concentrations	 of	 polymer,	 but	 as	 the	






Fluorescent	 dye-encapsulated	 NPs	 were	 delivered	 to	 developing	 mouse	 fetuses	
through	 intra-amniotic	 (IA)	 injection	 at	 gestational	 ages	 E15-E18	 and	 through	
intravenous	 (IV)	 injection	 at	 gestational	 ages	 E15-E16.	 At	 gestational	 ages	 above	
E16,	the	involution	of	the	vitelline	vein	through	which	the	IV	injections	are	delivered	
inhibits	consistent	and	effective	injection	of	NPs.	Successful	injections	of	fluorescent	
NPs	 were	 confirmed	 by	 stereomicroscopy	 images	 of	 the	 fetuses	 3	 hours	 after	
injection	of	fluorescent	NPs	(FIGURE	3).	For	IA	injections,	images	were	taken	with	
amniotic	sac	intact	to	show	fluorescence	within	the	amniotic	fluid.	For	IV	injections,	






allow	maturation	 and	 growth	 of	 the	 respiratory	 and	 alimentary	 tracts.	 Temporal	
and	spatial	 targeting	of	nanoparticles	 is	 therefore	possible	 to	 these	organ	systems	
once	the	fetus	has	initiated	these	actions.	Intra-amniotic	injection	of	fluorescent	NPs	
at	 days	 E15-E18	 of	 gestation	 and	 subsequent	 histological	 analysis	 demonstrated	
that	at	gestational	age	E16,	NPs	are	evident	throughout	the	developing	lungs	as	well	





different	 patterns	 of	 accumulation	 within	 the	 organs	 of	 the	 fetuses.	 Whole	 fetus	
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fluorescent	 x-ray	 imaging	was	performed	 (FIGURE	 5).	 For	 IV	 injected	 fetuses,	 the	
imaging	demonstrates	a	bright	focal	accumulation	in	the	abdomen	of	the	fetus	that	
correlates	 to	 the	 area	 of	 the	 liver.	 In	 contrast,	 for	 IA	 injected	 fetuses,	 fluorescent	








another	 extensive	 capillary	 bed	 in	 which	 NPs	 would	 accumulate,	 also	 show	
moderate	 uptake	 of	 fluorescence.	 In	 the	 IA	 injected	 fetuses,	 as	 confirmed	 by	
histology,	there	is	no	uptake	in	those	fetuses	injected	at	E15	days.	However,	starting	






barrier	 between	 maternal	 and	 fetal	 circulations.	 Should	 NPs	 enter	 into	 maternal	
circulation,	 they	 would	 be	
expected	 to	 undergo	 first-pass	
hepatic	 uptake	 and	 therefore	
be	 noted	 on	 analysis	 of	
maternal	 liver.	 FIGURE	 6	
demonstrates	 that	 at	 E15	 and	
E16	days	gestation,	IV	injection	
does	 not	 result	 in	 detectable	










antigen	 location	within	 the	 tissues	of	 interest.	The	established	delivery	method	of	
nanoparticles	 via	 the	 amniotic	 fluid	 in	 a	 fetal	 model	 and	 intranasally	 in	 an	 adult	
model	 necessitates	 apical	 surface	 localization	 of	 the	 targets,	 such	 that	 antibody-	
conjugated	NPs	will	be	allowed	to	come	into	contact	with	the	correct	antigen.	CFBE	
cell	staining	with	anti-PDPN	and	anti-MUC1	antibodies	demonstrates	cell	membrane	






epithelial	 cells	 of	 the	 lungs,	 distributed	 throughout	 the	 large	 and	 small	 airways.	














Antibody	 titration	 curves	 for	 candidate	 surface	markers	 were	 created	 with	 CFBE	
cells	 to	 determine	 receptor	 density	 and	 antibody	 affinity	 properties.	 MUC1	
fluorescent	 intensity	 increased	 in	 a	 dose-dependent	 manner,	 while	 increasing	
concentrations	 of	 anti-PDPN	 and	 anti-SFTPC	 antibodies	 did	 not	 modulate	 the	
fluorescent	 signal	 (FIGURE	 10A).	 At	 30nM,	 a	 representative	 intermediate	
concentration,	 comparison	 of	 antibody	 binding	 compared	 to	 isotype	 is	 shown	 in	
FIGURE	 10B,	 demonstrating	 right-shifts	 of	 curves	 created	 by	 MUC1,	 ICAM,	 and	
CD227	antibodies.		When	fit	to	a	specific	binding	curve,	the	Kd	and	Bmax	values	can	
be	 calculated	 for	 MUC1,	 CD227,	 and	 ICAM	 (FIGURE	 10C).	 These	 values	 are	
representative	 of	 the	 antigen-antibody	 affinity	 and	 the	 receptor	 density,	
respectively.	 	 MUC1	 had	 the	 greatest	 Bmax	 (9191)	 indicating	 highest	 receptor	
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After	 treatment	with	 antibody-conjugated	 nanoparticles,	 CFBE	 cells	 demonstrated	
conjugation-dependent	 increased	uptake	 of	NPs	when	 conjugated	with	 anti-MUC1	
and	anti-ICAM	antibodies	(FIGURE	11).	When	noting	fold-increase	of	targeting	NPs	
















the	United	 States	 cystic	 fibrosis	 (CF)	 is	 the	 second	most	 common	 lethal	 inherited	
disorder	of	childhood,	with	a	prevalence	of	1/3700	births	(7,	8).	The	most	common	
mutation	 in	 CF	 is	 a	 three	 base-pair	 deletion	 (delF508)	 resulting	 in	 lack	 of	 cell	
surface	 expression	 of	 the	 cystic	 fibrosis	 transmembrane	 conductance	 regulator	
(CFTR)	 channel	 (7).	 Though	 it	 is	 one	of	 the	most	 rigorously	 characterized	 genetic	
diseases,	treatment	for	CF	focuses	on	symptom	management.	Gene	therapy	remains	
elusive	due	 to	 challenges	with	 efficient	 in	vivo	 delivery	 in	 the	postnatal	 host	 (76).	
The	burden	of	genetic	diseases	such	as	CF	represents	an	unmet	need	with	 lifelong	
morbidity	and	premature	mortality	resulting	from	a	process	that	could	be	amenable	
to	 cure	 by	 gene	 therapy.	 In	 utero	 delivery	 of	 targeting	 nanoparticles,	 therefore,	





takes	 advantage	of	 the	 fetus’	 immunotolerant	 status	 as	well	 as	 small	 relative	 size.	
Importantly,	the	developing	fetus	is	composed	of	proportionally	greater	numbers	of	
stem	 cells,	 which	 have	 been	 shown	 to	 be	 more	 susceptible	 to	 editing	 during	
development	 due	 to	 their	 massive	 proliferation	 and	migration	 (66-70).	 Access	 to	
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stem	cells	has	implications	for	permanent	and	exponential	impact	of	gene	editing,	as	
each	 progeny	 cell	 would	 contain	 the	 corrected	 genetic	 sequence.	 Unfortunately,	
these	 progenitor	 cells	 may	 no	 longer	 be	 accessed	 after	 birth.	 Prior	 work	 by	 our	
group	 has	 shown	 increased	 efficiency	 of	 gene	 editing	 in	 hematopoietic	 stem	 cells	




Intervening	 during	 development	 has	 the	 potential	 for	 increased	 and	 prolonged	
overall	 impact	 by	mitigating	 disease	 phenotypes	 before	 birth.	 Nanoparticles	 have	









can	 result	 in	 mutation	 correction	 in	 a	 model	 of	 cystic	 fibrosis	 (58).	 However,	 by	
intranasal	administration	in	adult	mice,	correction	within	the	cells	of	the	lungs	was	
only	 1%,	 which	 is	 not	 sufficient	 to	 improve	 disease	 phenotype.	 Studies	 have	




well	 characterized	 cystic	 fibrosis	 bronchial	 epithelial	 cell	 line	 (81,	 82)	 as	 well	 as	





application	 of	 nanoparticles.	 We	 therefore	 set	 out	 to	 first	 determine	 the	
biodistribution	 of	 nanoparticles	 in	 a	 fetal	 mouse	 model.	 While	 physiologic	
movements	such	as	swallowing	and	breathing	have	been	well	characterized	 in	the	
human	fetus	(43,	83),	we	here	used	a	fetal	mouse	model	to	better	characterize	these	
actions	 in	mice.	 The	 comparison	of	 organ	 system	development	 between	mice	 and	
humans	 has	 also	 been	 widely	 studied,	 allowing	 for	 translation	 of	 our	 findings	 to	
clinically	relevant	time	points	(84).	Examination	of	fetal	organs	after	intra-amniotic	
injection	of	fluorescent	nanoparticles	demonstrated	that	at	gestational	day	15,	there	
are	 no	 particles	within	 the	 respiratory	 or	 gastrointestinal	 tracts	 of	 the	 fetal	mice.	
However,	 starting	 at	 E16	 days	 gestation	 and	 increasing	 in	 intensity	 through	 E18,	
significant	 nanoparticle	 accumulation	 is	 noted	 throughout	 the	 lungs	 and	 the	
intestines.	The	pattern	of	nanoparticle	distribution	is	consistent	with	literature	that	




optimize	 targeting.	 By	 intra-amniotic	 injection,	 therapies	 aimed	 at	 ameliorating	
respiratory	 or	 gastrointestinal	 diseases	 can	 be	 readily	 delivered	 to	 the	 organs	 of	




with	 amniocentesis,	 blood	 transfusions	 through	 the	 umbilical	 vein	 of	 the	 human	
fetus	have	been	safely	performed	for	many	years	(14)	and	provide	a	viable	method	
of	in	utero	delivery	of	nanoparticles.	Following	intravenous	injection	of	fluorescent	
nanoparticles	 there	 is	high	accumulation	 in	 the	 liver	of	E15	and	E16	 fetuses.	This	
finding	is	supported	in	other	studies	that	have	long	shown	that	there	is	intense	and	
rapid	hepatic	uptake	of	 intravenously	 injected	vessels	 (87,	 88).	At	E15,	 there	 also	









their	 untreated	 counterparts.	 Additionally,	 we	 showed	 in	 this	 study	 that	 the	




within	 the	 maternal	 livers	 that	 were	 examined.	 Finally,	 the	 dose	 of	 particles	 we	
deliver	 to	 the	 fetuses	 is	 substantially	 lower	 than	 the	 systemic	 doses	 that	must	 be	
delivered	 to	 adult	 mice.	 In	 studies	 with	 adult	 mice,	 5-7mg	 of	 nanoparticles	 are	
required	(36,	58),	while	fetal	injections	require	over	20	times	less.	If	similar	effects	
can	 be	 achieved	with	 smaller	 doses,	 the	 fetal	model	 is	 both	 cheaper	 and	 safer	 in	
practice.	
	
Taken	 together,	both	 route	of	administration	and	 timing	of	 injection	contribute	 to	
initial	 passive	 targeting	 of	 nanoparticles	 in	 utero.	 Specific	 organs	 can	 be	
differentially	 targeted	 by	 either	 amniotic	 or	 venous	 injection.	 Similarly,	 the	
developmental	stage	of	gestation	can	further	dictate	the	differential	accumulation	of	
particles	based	on	the	breathing	and	swallowing	patterns	of	the	fetus.	Importantly,	
stem	 cell	 migration	 and	 expansion	 patterns	 also	 change	 over	 development	 and	





be	 made,	 including	 conjugation	 of	 cell-specific	 antibodies.	 Based	 on	 our	
biodistribution	studies,	we	can	reliably	access	tissues	of	interests.	If	we	can	increase	
the	 contact	 time	 and	 therefore	 uptake	 of	 the	 nanoparticles	 into	 those	 tissues,	 the	
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specificity	of	delivered	therapeutics	can	be	increased.	Subsequently,	if	the	particles	
are	 more	 efficient,	 we	 can	 reduce	 the	 systemic	 dose	 delivered	 and	 decrease	 the	
potential	 for	 toxicity.	 To	maximize	 targeting	 potential	 it	 is	 important	 to	 optimize	
accessibility	 of	 the	 receptor,	 density	 of	 the	 receptor,	 and	 antibody-antigen	 affinity	
(53,	59,	74).	Therefore,	to	improve	upon	the	CF	phenotype	in	the	lung,	the	antigens	
must	 localize	 to	 the	 apical	 surface	 of	 epithelial	 cells	 where	 they	 would	 come	 in	
contact	 with	 inhaled	 nanoparticles.	 Visualization	 of	 the	 targets	 was	 achieved	 by	
immunohistochemistry,	which	showed	diffuse	surface	distributions	of	the	receptors	
on	 both	 the	 adult	 human	 CFBE	 cells	 lines	 as	 well	 as	 the	 fetal	 lung	 sections	 we	
examined.	 When	 comparing	 staining	 patterns	 between	 the	 fetal	 and	 adult	
respiratory	 epithelium,	 it	 appears	 as	 though	 mucin	 1	 (MUC1)	 retains	 diffuse	
expression	 throughout	 the	 large	 and	 small	 airways.	However,	 podoplanin	 (PDPN)	
and	surfactant	protein	C	(SFTPC),	while	staining	throughout	the	airways	in	the	fetal	




However,	 accessibility	 of	 the	 antigen	 is	 not	 sufficient	 for	 targeting	 purposes.	 We	
therefore	 created	 antibody	 binding	 curves	 based	 on	 dose-dependent	 binding	 of	
antibodies	 to	 CFBE	 cells.	 Of	 our	 initial	 targets,	 binding	 results	 from	 antibodies	
against	 MUC1,	 CD227	 (a	 different	 epitope	 on	 the	 mucin	 1	 receptor),	 and	






of	MUC1	 approached	10,000,	 representing	 the	 highest	 receptor	 density.	However,	
the	Kd	value	of	ICAM	was	strongest	at	0.014,	indicating	the	highest	binding	affinity.	




nanoparticles	 and	 in	vitro	 treatment	of	CFBE	 cells	 at	different	 concentrations.	Not	
surprisingly,	 good	 receptor	 density	 and	 antibody	 affinity	 by	 binding	 curve	
translated	 into	 conjugation-dependent	 uptake	 of	 antibody-conjugated	
nanoparticles.	 When	 compared	 to	 an	 isotype	 control,	 both	 MUC1	 and	 ICAM	
demonstrated	increased	nanoparticle	uptake,	with	a	four-fold	increase	in	uptake	for	




particles	 can	 diffuse	 to	 contact	 the	 cell	 surface.	 Other	 studies	 have	 shown	 similar	
results	of	conjugation-dependent	nanoparticle	uptake.	These	studies,	using	different	
cells	 and	 markers,	 have	 shown	 up	 to	 80-fold	 increase	 of	 uptake	 (53-55,	 89,	 90).	




Of	 the	 targets	 we	 tested,	 MUC1	 and	 ICAM	 demonstrated	 the	 greatest	 increase	 in	
uptake.	MUC1	 is	part	of	 the	mucin	 family	of	 genes	 found	on	epithelial	 cells	 and	 is	
expressed	on	apical	surface	of	epithelial	cells	that	line	the	mucosal	surfaces	of	many	
different	 tissues,	 including	 the	 lung	 (91-93).	 In	 fact,	MUC1	 is	upregulated	 in	many	
epithelial	cancers	and	is	 therefore	a	common	cancer	target.	Successful	 targeting	of	
this	protein	has	been	shown	in	other	studies	(94,	95),	further	validating	our	results.	
Interestingly,	 MUC1	 is	 also	 found	 in	 stomach	 and	 pancreas,	 which	 could	 have	
additional	implications	for	targeting	cystic	fibrosis,	as	these	organs	are	also	affected.	




ICAM-conjugated	nanoparticles	were	also	 found	to	result	 in	consistently	 increased	
uptake	 in	CFBE	cells.	Though	often	thought	of	as	an	endothelial	cell	marker,	 ICAM	
has	 also	 been	 found	 to	 be	 involved	 in	 neutrophil	 recruitment	 via	 respiratory	
epithelium	(96).	Furthermore,	in	inflammatory	states	of	pulmonary	diseases	such	as	
CF,	ICAM	expression	is	upregulated	on	the	surface	of	respiratory	epithelium,	making	
this	an	even	more	significant	 receptor	 for	 therapeutic	 targeting	 (97).	Additionally,	






conjugated	 with	 anti-MUC1	 antibodies	 compared	 to	 anti-CD227	 antibodies.	 Both	
antibodies	 are	 specific	 to	 the	 MUC1	 protein,	 though	 the	 antibodies	 bind	 two	
different	epitopes.	On	analysis	of	the	antibody	binding	curves,	CD227	had	a	similar	
Bmax	compared	to	ICAM,	and	we	expected	these	nanoparticles	to	perform	at	least	as	
well	 as	 MUC1	 and	 ICAM.	 However,	 in	 practice,	 the	 CD227-specific	 nanoparticles	
demonstrated	only	a	slight	 increased	uptake	compared	to	control	nanoparticles	at	
the	 lowest	 dose.	 One	 possible	 explanation	 is	 the	 location	 of	 the	 CD227	 epitope.	
When	conjugating	antibodies	 to	significantly	 larger	nanoparticles,	steric	hindrance	
may	 prohibit	 binding	 of	 antibodies	 to	 their	 targets.	 Though	 the	 antibody	
independently	 was	 able	 to	 bind	 and	 produce	 a	 binding	 curve,	 this	 alone	 cannot	
guarantee	that	the	conjugated	nanoparticle	will	be	equally	successful.		
	
When	 creating	 antibody	binding	 curves	 for	 antibodies	 that	 appeared	 to	 be	 on	 the	
surface	 of	 CFBE	 cells	 by	 staining,	 both	 PDPN	 and	 SFTPC	 failed	 to	 produce	 dose-
dependent	specific	binding	curves.	Both	of	these	receptors	had	been	selected	after	a	
thorough	 literature	 search	 and	 validation	 in	 the	 LungGENS	 database,	 a	 single-cell	
gene	 expression	 database	 specific	 for	 fetal	 mouse	 lungs	 (72).	 We	 were	 further	
bolstered	by	the	high	apparent	expression	of	both	targets	throughout	the	airways	of	
fetal	 mice	 as	 determined	 by	 immunohistochemistry.	 There	 are	 several	 possible	
explanations	 for	 this	 unexpected	 outcome.	 First,	 it	 is	 possible	 that	 either	 the	
receptor	 density	 or	 the	 quality	 of	 the	 antibody	 itself	 were	 inadequate	 to	 be	 a	
successful	target.	Second,	although	fetal	mouse	lungs	exhibited	strong	expression	of	
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PDPN,	 when	 comparing	 to	 adult	 mouse	 lungs,	 there	 is	 a	 different	 pattern	 of	
expression	 and	 we	 may	 no	 longer	 be	 targeting	 the	 correct	 cells.	 Differential	
expression	 of	 PDPN	 has	 been	 demonstrated	 between	 fetal	 and	 adult	 lungs	 and	
therefore	 age	 may	 affect	 the	 available	 receptors	 (98).	 Finally,	 even	 though	 fetal	
mouse	lungs	appeared	to	have	a	strong	signal,	the	antibody	binding	curve	is	created	










presented	 in	 the	 literature	 that	 could	 address	 this	 limitation	 is	 quantitative	
microscopy	 (53).	 Using	 sections	 of	 fetal	 mouse	 lung	 and	 identical	 staining	 and	
imaging	techniques,	it	may	be	possible	to	create	dose-dependent	curves	and	thereby	
estimate	 the	 receptor	 density	 and	 antibody-antigen	 affinity	 in	 situ.	 Similarly,	
translation	between	species,	 in	this	case	human	and	mouse,	 is	not	always	possible	
and	therefore	the	identification	and	characterization	of	targets	should	be	performed	




There	 are	 several	 future	 studies	 to	 be	 performed	 to	 expand	 upon	 the	 results	
presented	 in	 this	 study.	While	 we	were	 able	 to	 demonstrate	 increased	 uptake	 of	
nanoparticles	into	cells,	the	therapeutic	efficacy	of	the	particles	is	dependent	on	the	
ability	 to	deliver	 the	payload	 (99).	 In	 the	 context	 of	 our	 study,	 the	next	 step	 is	 to	
demonstrate	that	preferential	collection	of	particles	in	our	target	cells	indeed	leads	
to	 higher	 rates	 of	 gene	 editing.	 Subsequently,	 we	 will	 also	 be	 performing	 in	 vivo	
conjugation	 studies.	With	 the	use	of	 quantitative	microscopy	and	FACS	 to	 analyze	
differential	 uptake,	we	 hope	 to	 show	 improved	 efficacy	 of	 targeting	 nanoparticles	
into	the	lungs	of	a	fetal	mouse	model.	Finally,	our	group	has	ongoing	studies	further	
modifying	 the	 molecular	 characteristics	 of	 particles,	 including	 the	 size	 of	 the	
particles	as	well	as	the	polymer	type.	It	has	been	shown	that	size	and	composition	of	
particles	can	also	affect	the	biodistribution	and	therefore	can	impact	targeting	(42,	
99-101).	 Thus,	 while	 our	 data	 demonstrates	 increased	 uptake	 efficiency	 and	
specificity	 with	 targeting	 nanoparticles,	 further	 work	 is	 warranted	 to	 continue	
optimizing	this	technology.		
	
In	 summary,	we	present	here	new	 insights	 into	 targeting	nanoparticles	 to	 specific	
cell	 and	 tissue	 types,	 both	 in	vitro	 and	 in	vivo.	We	 have	 demonstrated	 differential	
biodistribution	 after	 in	 utero	 injection	 of	 nanoparticles	 that	 can	 be	 reproducibly	
altered	 to	 target	 specific	organs.	Furthermore,	we	have	demonstrated	 that	we	can	
increase	uptake	of	nanoparticles	in	a	conjugation-dependent	manner	to	further	help	
to	 increase	our	 targeting	efficiency.	This	work	provides	 the	 foundation	 for	 further	
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study	 into	 targeting	 in	vivo,	 both	 in	 adult	 and	 fetal	mouse	models,	 so	 that	we	 can	
obtain	greater	therapeutic	efficacy	via	nanoparticle	delivery.	Indeed,	imminent	work	
from	our	group	will	seek	to	demonstrate	greater	gene	editing	efficiency	in	a	cystic	
fibrosis	 model	 in	 the	 hopes	 of	 achieving	 phenotypic	 improvement.	 Targeting	
technology	can	be	applied	to	a	wide	range	of	therapies	and	disorders,	and	 in	utero	
application	of	 this	 technology	 increases	 the	 therapeutic	potential	of	nanoparticles.	
Future	work	will	influence	our	understanding	of	disease	and	the	outcomes	of	many	
congenital	disorders.		
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